U.S. Next-generation Sequencing Services Market Overview

The U.S. next-generation sequencing services market size was estimated at around USD 2.51 billion in 2023 and it is projected to hit around USD 18.98 billion by 2033, growing at a CAGR of 22.42% from 2024 to 2033.

Next-Generation Sequencing (NGS) refers to a suite of advanced sequencing technologies that allow for the rapid and cost-effective sequencing of entire genomes, exomes, or targeted gene panels. Unlike traditional Sanger sequencing, NGS can process millions of DNA fragments simultaneously, providing a comprehensive view of genetic variations, mutations, and gene expression profiles. This high-throughput approach has revolutionized fields such as genomics, oncology, personalized medicine, and evolutionary biology.

Key Highlights:

• Human genome sequencing generated the highest revenue with a 33% share in 2023.
• Gene regulation services are projected to grow fastest during the forecast period.
• Sequencing services dominated the workflow segment with a 56% market share in 2023.
• Pre-sequencing services are expected to expand at the fastest rate from 2024 to 2033.

Get Sample@ https://www.visionresearchreports.com/report/sample/41366

Emerging Trends in U.S. NGS Services

1. Integration of AI and Machine Learning: The integration of artificial intelligence (AI) and machine learning algorithms is transforming NGS data analysis. These technologies enhance the accuracy of variant calling, improve data interpretation, and enable more efficient data management. AI-driven tools are becoming increasingly important for processing the massive amounts of data generated by NGS.
2. Expansion into Clinical Diagnostics: Clinical applications of NGS are expanding rapidly, particularly in oncology, rare disease diagnostics, and prenatal screening. NGS is increasingly being used for personalized medicine, where genomic data guides tailored treatment plans. The rise of liquid biopsies, which detect cancer-related mutations from blood samples, is a notable trend in this area.
3. Advancements in Sequencing Technologies: Innovations in sequencing technologies, such as long-read sequencing and nanopore sequencing, are providing new insights into complex genomic regions and structural variants that were previously challenging to analyze. These advancements are pushing the boundaries of genomics research and clinical diagnostics.
4. Cost Reduction and Accessibility: As sequencing technologies continue to evolve, the cost of sequencing is decreasing, making it more accessible to a broader range of researchers and clinicians. This trend is democratizing genomics research and fostering greater innovation across various fields.
5. Growth of Genomic Data Repositories: The establishment and expansion of genomic data repositories, such as the Genome Aggregation Database (gnomAD) and the Genomic Data Commons (GDC), are providing valuable resources for researchers. These repositories facilitate large-scale data sharing and collaboration, accelerating discoveries and advancements in genomics.

U.S. Next-generation Sequencing Services Market Opportunities

• Personalized Medicine: The shift towards personalized medicine presents significant opportunities for NGS service providers. By offering targeted sequencing solutions and tailored genomic analysis, companies can cater to the growing demand for precision medicine.
• Pharmacogenomics: The application of NGS in pharmacogenomics, which studies how genes affect a person’s response to drugs, offers potential for developing personalized drug therapies and improving patient outcomes.
• Expanding into Emerging Markets: While the U.S. market is well-established, there is growing interest in expanding NGS services into emerging markets where genomic research and healthcare infrastructure are developing.

U.S. Next-generation Sequencing Services Market Challenges

• Data Management: Handling and analyzing the vast amounts of data generated by NGS can be challenging. Developing robust data management and analysis solutions is crucial for maintaining data quality and integrity.
• Regulatory and Ethical Issues: As NGS becomes more integrated into clinical practice, navigating regulatory and ethical considerations becomes increasingly important. Ensuring compliance with regulations and addressing ethical concerns related to genetic data is essential for maintaining public trust.
• Technical Limitations: Despite advancements, there are still technical limitations to NGS, such as challenges in sequencing highly repetitive regions of the genome and achieving uniform coverage across different samples.

Read More@ https://www.heathcareinsights.com/asia-pacific-bioanalytical-testing-services-market-navigating-the-future/

U.S. Next-generation Sequencing Services Market Top Companies

• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Eurofins Scientific SE
• PerkinElmer, Inc.
• QIAGEN
• Quest Diagnostics Incorporated
• Azenta Life Sciences (GENEWIZ)
• NanoString
• PacBio
• bioMérieux
• BGI Group
• F. Hoffmann-La Roche Ltd
• ARUP Laboratories
• Novogene Co, Ltd.
• Gene by Gene Ltd.
• Lucigen Corporation

Recent Market News

• In April 2022, LGC acquired Rapid Genomics to strengthen its position in NGS applications and offer advanced solutions to the agricultural sector. This acquisition enhances their capabilities in genetic analysis for crop improvement and animal breeding.
• In March 2022, LetsGetChecked, a prominent health testing company, acquired Veritas Genetics to leverage their genome sequencing services. This move enables LetsGetChecked to provide more comprehensive and personalized health insights to their customers.
• In July 2021, ARUP Laboratory opened a state-of-the-art facility spanning 220,000 sq. ft. at the University of Utah Research Park in the U.S. The lab’s objective is to enhance the quality of laboratory testing and support research advancements.

U.S. Next-generation Sequencing Services Market Segmentation:

By Service Type

• Human Genome Sequencing Services
• Single Cell Sequencing Services
• Microbial Genome-based Sequencing Services
• Gene Regulation Services
  • ChIP Sequencing Service
  • Small RNA Sequencing Service
  • Other Gene Regulation-based Service
• Animal & Plant Sequencing Services
• Other Sequencing Services

By Workflow

• Pre-sequencing Service
• Sequencing Service
• Data Analysis Service

By End-use

• Universities & Other Research Entities
• Hospitals & Clinics
• Pharma & Biotech Entities
• Other End-uses